Related Experiment Video
Updated: Jun 15, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
"Metronomic" chemotherapy in advanced soft tissue sarcomas
Antoine Italiano1, Maud Toulmonde, Barbara Lortal
1Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France. italiano@bergonie.org
Cancer Chemotherapy and Pharmacology
|February 26, 2010
Summary
Metronomic etoposide showed clinical activity in metastatic soft tissue sarcomas (STS). Further studies are needed to determine which patients benefit most from this chemotherapy approach.
Area of Science:
- Oncology
- Medical Oncology
- Cancer Research
Background:
- Angiogenesis is critical for metastatic progression in soft tissue sarcomas (STS).
- Endothelial cells are key targets for metronomic chemotherapy.
- Metronomic chemotherapy offers a potential treatment strategy for STS.
Purpose of the Study:
- To evaluate the safety and efficacy of metronomic etoposide in patients with metastatic STS.
- To assess clinical activity and survival outcomes in this patient population.
Main Methods:
- Retrospective review of 26 metastatic STS patients treated with metronomic etoposide (100 mg/day for 21 days, every 4 weeks).
- Data collection included patient demographics, prior treatments, response rates, progression-free survival (PFS), and overall survival (OS).
Main Results:
- Partial response in 4% and stable disease for >24 weeks in 42% of patients.
- 6-month PFS rate: 42%; 1-year PFS rate: 23%.
- 6-month OS rate: 69%; 1-year OS rate: 31%.
- Grade 4 febrile neutropenia occurred in 2 patients, with one sepsis-related death.
Conclusions:
- Metronomic etoposide demonstrated significant clinical activity in metastatic STS.
- Further prospective studies are required to identify patient subgroups likely to benefit from this treatment strategy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...